{"certainAgreement":{"otherDetails":"The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review, should the submission for publication be delayed in order to file patent application. The sponsor cannot require changes to the communication and cannot extend the embargo.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"pointOfContact":{"email":"information.center@astrazeneca.com","organization":"AstraZeneca Clinical Study Information Center","phone":"1-877-240-9479","title":"Global Clinical Lead"}}